memantine has been researched along with Abnormal Movements in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study addresses the effects of 52 weeks of treatment with the NMDA glutamate receptor antagonist memantine on motor, cognitive, and mental disorders in patients with Parkinson's disease complicated by dementia, as compared with a control group of patients not treated with memantine." | 9.14 | Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia. ( Litvinenko, IV; Mogil'naya, VI; Odinak, MM; Perstnev, SV, 2010) |
| " Treatment with memantine prevented the chorea movement and the progression of Huntington's disease." | 8.31 | Memantine administration prevented chorea movement in Huntington's disease: a case report. ( Hirano, M; Ikegawa, A; Kusunoki, S; Mitsui, Y; Nagai, Y; Oda, I; Saigoh, K; Samukawa, M; Yamagishi, Y; Yoshikawa, K, 2023) |
| "After some years with Parkinson's disease patients tend to develop fluctuating symptoms and dyskinesia with involuntary movements--a state difficult to manage." | 5.32 | [Memantine can relieve certain symptoms in Parkinson disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure]. ( Lökk, J, 2004) |
| "This study addresses the effects of 52 weeks of treatment with the NMDA glutamate receptor antagonist memantine on motor, cognitive, and mental disorders in patients with Parkinson's disease complicated by dementia, as compared with a control group of patients not treated with memantine." | 5.14 | Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia. ( Litvinenko, IV; Mogil'naya, VI; Odinak, MM; Perstnev, SV, 2010) |
| " Treatment with memantine prevented the chorea movement and the progression of Huntington's disease." | 4.31 | Memantine administration prevented chorea movement in Huntington's disease: a case report. ( Hirano, M; Ikegawa, A; Kusunoki, S; Mitsui, Y; Nagai, Y; Oda, I; Saigoh, K; Samukawa, M; Yamagishi, Y; Yoshikawa, K, 2023) |
| "After some years with Parkinson's disease patients tend to develop fluctuating symptoms and dyskinesia with involuntary movements--a state difficult to manage." | 1.32 | [Memantine can relieve certain symptoms in Parkinson disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure]. ( Lökk, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saigoh, K | 1 |
| Hirano, M | 1 |
| Mitsui, Y | 1 |
| Oda, I | 1 |
| Ikegawa, A | 1 |
| Samukawa, M | 1 |
| Yoshikawa, K | 1 |
| Yamagishi, Y | 1 |
| Kusunoki, S | 1 |
| Nagai, Y | 1 |
| Tronci, E | 1 |
| Fidalgo, C | 1 |
| Zianni, E | 1 |
| Collu, M | 1 |
| Stancampiano, R | 1 |
| Morelli, M | 1 |
| Gardoni, F | 1 |
| Carta, M | 1 |
| Litvinenko, IV | 1 |
| Odinak, MM | 1 |
| Mogil'naya, VI | 1 |
| Perstnev, SV | 1 |
| Lökk, J | 1 |
1 trial available for memantine and Abnormal Movements
| Article | Year |
|---|---|
Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cognition; Cognition Disorders; Dementia; Di | 2010 |
3 other studies available for memantine and Abnormal Movements
| Article | Year |
|---|---|
Memantine administration prevented chorea movement in Huntington's disease: a case report.
Topics: Aged; Alzheimer Disease; Chorea; Dyskinesias; Female; Humans; Huntington Disease; Iofetamine; Male; | 2023 |
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Excitatory Amino Aci | 2014 |
[Memantine can relieve certain symptoms in Parkinson disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure].
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Dopamine Agents; Dyskinesias; Female; Humans; Male; | 2004 |